Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Globe Newswire•29/07/2026•20:57 ET
0
Whiz Insights
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases
Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain
Get started
Create a free account to read the full story.